NCT06385678

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Phase IB/II Clinical Study on the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Medication in Subjects With Advanced Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.

Conditions

• Advanced KRAS G12D Mutant Solid Tumors

Interventions

Type	Name	Description
DRUG	HRS-4642	administrated per dose level in which the patients are assigned
DRUG	Adebrelimab	administrated per dose level in which the patients are assigned
DRUG	SHR-9839	administrated per dose level in which the patients are assigned
DRUG	Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection	administered as prescribed by the investigator.
DRUG	Cetuximab Solution for Infusion	administrated per dose level in which the patients are assigned

Timeline

• Start date: 2024-07-05
• Primary completion: 2025-12-01
• Completion: 2026-08-01
• First posted: 2024-04-26
• Last updated: 2025-09-19

Locations

1 site across 1 country: China